Development And Evaluation Of Lamivudine Sustained Release Matrix Tablets
Date
2019-08
Journal Title
Journal ISSN
Volume Title
Publisher
Bimonthly published online Journal
Abstract
Lamivudine is approved for clinical use and used widely in treatment of Hepatitis Band AIDS either alone or in combination with another antiviral drugs because of its watersolubility and shorter half-life (5-7 hrs) drug requires frequent dosing by oral route, off variousrecent techniques for controlling drug release, matrix system offer various advantages of easeof formulation better control on release profile of drug and better patient compliance. Thematrix tablets formulation by direct compression method is most acceptable in large scaleproduction. It is concluded that formulation of sustained release tablet of Lamivudinecontaining 80 mg of hydroxypropyl-methylcellulose E15 (high viscosity grade) and 80 mg ofethylcellulose i.e. formulation F7 can be taken as an ideal or optimized formulation ofsustained release tablets for 16 hours release as it fulfills all the requirements for sustainedrelease tablet and our study encourages for the further clinical trials and long term stabilitystudy on this formulation.
Description
Keywords
Sustained Release, Lamivudine, Matrix Tablet, Hepatitis B
Citation
Singh Than, Asija Rajesh, Goyal Anil Kumar. Development And Evaluation Of Lamivudine Sustained Release Matrix Tablets. International Journal of Pharmaceutical Research and Bioscience (IJPRBS). 2019 Aug; 8(4): 139-176